Cooperative Immune-mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL-15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
CONCLUSIONS: Collectively, these data demonstrate that the synergistic combination of entinostat, N-803, and vaccine elicits potent anti-tumor activity by generating a more inflamed TME. These findings thus form the rationale for the use of this combination of agents for patients harboring poorly or non-inflamed solid carcinomas.
PMID: 31645354 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Hicks KC, Knudson KM, Lee KL, Hamilton DH, Hodge JW, Figg WD, Ordentlich P, Jones FR, Rabizadeh S, Soon-Shiong P, Schlom J, Gameiro SR Tags: Clin Cancer Res Source Type: research
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Carcinoma | Colon Cancer | Colorectal Cancer | Genetics | Immunotherapy | Vaccines